MAZE — Maze Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1842295 ·
Last close
$26.05
Market Cap
$1.45B
52W High
$53.65
52W Low
$21.95
ADV30
654,553
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -48,035,000 | -44,727,000 | 531,625,000 | 202,643,000 | 78,501,000 |
| Mar 2026 | 20,000,000 | — | -26,553,000 | -24,208,000 | 419,710,000 | 198,766,000 | 78,009,000 |
| Dec 2025 | 0 | — | -38,059,000 | -34,568,000 | 397,127,000 | 189,247,000 | 42,161,000 |
| Sep 2025 | 0 | — | -32,965,000 | -30,087,000 | 422,058,000 | 316,773,000 | 42,622,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-121,537,000
Investing CF
$-164,388,000
Financing CF
$190,316,000
CapEx
$-588,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.53
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-513,755,000
Inventory
—
Receivables
$20,000,000
ST Investments
$153,616,000
EBIT TTM
$-130,840,000
Pretax Income TTM
$-122,542,000
Interest Exp TTM
$866,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,000,000
EBITDA
$-143,707,008
Free Cash Flow
$-63,627,624
Enterprise Value
$1,015,845,504
Total Cash
$411,087,008
Total Debt
$60,423,000
Shares Out
55,549,168
Trailing EPS
$-2.44
Book Value
$8.16
ROE
-37.3%
ROA
-21.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -142,899,000 | -131,120,000 | 397,127,000 | 42,161,000 | 354,966,000 | -111,940,000 |
| Dec 2024 | 167,500,000 | 57,586,000 | 52,231,000 | 240,542,000 | 551,725,000 | -311,183,000 | 75,954,000 |
| Dec 2023 | 0 | -98,551,000 | -100,415,000 | 71,504,000 | 445,352,000 | -373,848,000 | -86,827,000 |
| Dec 2022 | 0 | -111,026,000 | -114,940,000 | 149,957,000 | 432,416,000 | -282,459,000 | -99,203,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.18
Max Pain — expiry 2026-11-20
max pain strike: $30.00 · spot: $25.35 · call oi: 1,170 · put oi: 949
Expected Move to 2026-11-20:
±$6.17
(24.33%) —
implied range
$19.18 –
$31.52
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INBX | Inhibrx Biosciences, Inc. | $1.47B | $99.61 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.52B | $4.67 | — |
| IMCR | Immunocore Holdings plc | $1.58B | $30.72 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.62B | $34.74 | — |
| IMTX | Immatics N.V. | $1.27B | $8.37 | — |
News headlines (Yahoo Finance, 1h cache)
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
2026-09-25 04:23 · Yahoo
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
2026-09-23 12:48 · Yahoo
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
2026-09-11 20:07 · Yahoo
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
2026-09-02 11:00 · Yahoo
Maze Therapeutics Announces Appointments to Its Board of Directors
2026-08-13 20:42 · Yahoo
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
2026-08-11 20:01 · Yahoo
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
2026-07-21 13:55 · Yahoo
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
2026-06-29 13:06 · Yahoo
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now
2026-06-08 03:44 · Yahoo
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
2026-06-05 19:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.